Get the Stockscreener App
16.97
0.30%
0.05
Theravance Biopharma Inc stock is traded at $16.97, with a volume of 405.44K.
It is up +0.30% in the last 24 hours and up +0.30% over the past month.
Theravance Biopharma Inc is a biopharmaceutical company focused on the development and commercialization of medicines to improve patients lives. The company leverages decades of expertise and has developed FDA-approved YUPELRI (revefenacin) inhalation solution for the maintenance treatment of patients with COPD. Its ampreloxetine Phase 3 clinical study (CYPRESS) for the treatment of symptomatic neurogenic orthostatic hypotension in patients with multiple system atrophy did not meet its primary endpoint. The company operates in a single segment, the development and commercialization of human therapeutics, and operates in the United States, which generates maximum revenue, and Europe.
See More
Previous Close:
$16.92
Open:
$16.91
24h Volume:
405.44K
Relative Volume:
0.65
Market Cap:
$881.06M
Revenue:
$109.78M
Net Income/Loss:
$114.54M
P/E Ratio:
7.6975
EPS:
2.2046
Net Cash Flow:
$268.74M
1W Performance:
+0.24%
1M Performance:
+0.30%
6M Performance:
-13.11%
1Y Performance:
+31.14%
1-Day Range:
$16.91
$16.99
1-Week Range:
$16.88
$16.99
52-Week Range:
$12.79
$21.03
Theravance Biopharma Inc Stock (TBPH) Company Profile
Name
Theravance Biopharma Inc
Sector
Industry
Phone
650-808-6000
Address
UGLAND HOUSE, SOUTH CHURCH STREET, GEORGE TOWN, GRAND CAYMAN
Compare TBPH vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TBPH
Theravance Biopharma Inc
|
16.97 | 878.47M | 109.78M | 114.54M | 268.74M | 2.2046 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Theravance Biopharma Inc Stock (TBPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-05-26 | Downgrade | Oppenheimer | Outperform → Perform |
| Mar-04-26 | Downgrade | B. Riley Securities | Buy → Neutral |
| Dec-03-25 | Initiated | Oppenheimer | Outperform |
| Sep-12-25 | Initiated | B. Riley Securities | Buy |
| Aug-06-24 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Apr-12-24 | Initiated | BTIG Research | Buy |
| Jan-08-24 | Downgrade | Evercore ISI | Outperform → In-line |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Nov-05-21 | Upgrade | JP Morgan | Underweight → Neutral |
| Sep-15-21 | Downgrade | JP Morgan | Overweight → Underweight |
| Aug-25-21 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Aug-24-21 | Downgrade | Cowen | Outperform → Market Perform |
| Oct-14-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jul-07-20 | Initiated | JP Morgan | Overweight |
| Jun-15-20 | Initiated | Morgan Stanley | Equal-Weight |
| May-13-20 | Initiated | Cowen | Outperform |
| Jan-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-06-19 | Upgrade | Robert W. Baird | Underperform → Neutral |
| Oct-29-19 | Initiated | H.C. Wainwright | Buy |
| Mar-29-18 | Resumed | Piper Jaffray | Overweight |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jun-16-17 | Initiated | Cantor Fitzgerald | Overweight |
| May-11-17 | Reiterated | Needham | Buy |
| Dec-21-16 | Initiated | Needham | Buy |
| Nov-03-16 | Initiated | Piper Jaffray | Overweight |
| Oct-12-16 | Downgrade | Robert W. Baird | Neutral → Underperform |
| Aug-03-16 | Downgrade | BofA/Merrill | Neutral → Underperform |
| Jun-20-16 | Initiated | Guggenheim | Buy |
| Jun-20-16 | Reiterated | Leerink Partners | Outperform |
| May-12-16 | Initiated | Leerink Partners | Outperform |
| May-05-16 | Downgrade | BofA/Merrill | Buy → Neutral |
| Feb-03-15 | Upgrade | Robert W. Baird | Underperform → Neutral |
View All
Theravance Biopharma Inc Stock (TBPH) Latest News
Theravance Biopharma (TBPH): Newtyn discloses 6.7% holdings in amended 13G/A - Stock Titan
Theravance Biopharma (TBPH) investor group reports 17.7% beneficial stake - Stock Titan
(TBPH) Risk Channels and Responsive Allocation - Stock Traders Daily
Theravance Biopharma Announces Q2 2026 Financial Results with $10.8M Net Loss Amid Restructuring - Kalkine Media
TBPH Meets Q2 Earnings Estimates, to be Acquired by Zymeworks - Yahoo! Finance Canada
Theravance Biopharma (NASDAQ: TBPH) details $17 cash payout and ampreloxetine CVRs in Zymeworks deal - Stock Titan
Theravance Biopharma, Inc. 2026: Revenue $20.73M, EPS ($0.11) — 10-Q Summary - TradingView
Theravance Biopharma (TBPH) agrees $17 cash sale to Zymeworks plus CVRs - Stock Titan
Renaissance Technologies LLC Acquires New Holdings in Theravance Biopharma, Inc. $TBPH - MarketBeat
Theravance Biopharma earnings missed by $0.17, revenue fell short of estimates - Investing.com Canada
Theravance Biopharma Releases Q2 2026 Financial Results - AlphaStreet
Theravance Biopharma Q2 net loss turns to USD 5.9 million; revenue rises 11% to USD 20.7 million YoY - Bitget
Theravance Biopharma Q2 Results: Adj. EPS beats by 260% - scanx.trade
Theravance Biopharma (NASDAQ:TBPH) Announces Quarterly Earnings Results, Meets Expectations - MarketBeat
TBPH Looks 29.8% Undervalued on GF Value™ Amid Acquisition News - GuruFocus
Earnings Flash (TBPH) Theravance Biopharma Posts Q2 Net Loss $0.11 a Share, vs. FactSet Est of $0.07 EPS - marketscreener.com
Earnings Flash (TBPH) Theravance Biopharma, Inc. Reports Q2 Revenue $20.7M, vs. FactSet Est of $22.5M - marketscreener.com
Form 8K Theravance Biopharma Inc For: 10 August By Investing.com - Investing.com Nigeria
Theravance Biopharma Q2 2026: Viatris collaboration revenue $20.7M; net loss $5.9M; $388M cash - TradingView
Ireland's Theravance Biopharma Q2 revenue rises 11% but misses estimates - TradingView
Theravance Bio: Q2 Earnings Snapshot - marketscreener.com
BRIEF-Theravance Biopharma Q2 Operating Income USD -8.277 Million - TradingView
Press Release: Theravance Biopharma, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update - Moomoo
Theravance Biopharma (TBPH) Earnings Date and Reports 2026 - MarketBeat
Theravance Biopharma, Inc. $TBPH Shares Acquired by Dimensional Fund Advisors LP - MarketBeat
Theravance Biopharma, Inc. (TBPH) Stock Analysis: Strong Revenue Growth and High ROE Offer Intriguing Investment Prospects - directorstalkinterviews.com
Theravance Biopharma (TBPH) Expected to Announce Earnings on Tuesday - MarketBeat
Arrowstreet Capital Limited Partnership Sells 635,711 Shares of Theravance Biopharma, Inc. $TBPH - MarketBeat
(TBPH) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Theravance Biopharma, Inc. (TBPH) Stock Analysis: Evaluating a 4.85% Potential Upside Amidst Biotech Ambitions - directorstalkinterviews.com
Theravance Biopharma Inc (TBPH) Technical Analysis: Support, Resistance, Indicators & Moving Averages - tradingkey.com
Theravance Biopharma (TBPH) Holds Steady Near Support as Trading Volume Remains MutedMomentum Surge Alerts - dars.gov.et
TBPH Q2'26 Earnings: revenue estimate is 22.49M USD - TradingView
ETFs Investing in Theravance Biopharma Inc Stocks - TradingView
Theravance Biopharma Inc (TBPH) Cash Flow - TradingKey
TBPH|Theravance Biopharma Inc|Price:16.865|Chg%:+0.005 - TradingKey
103,000 Shares in Theravance Biopharma, Inc. $TBPH Purchased by Rangeley Capital LLC - MarketBeat
Theravance Biopharma Inc (TBPH) Balance Sheet - TradingKey
Theravance Biopharma Inc (TBPH) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Theravance Biopharma Inc (TBPH) Institutional Confidence - TradingKey
Theravance Biopharma Inc (TBPH) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Theravance Biopharma Inc Revenue Breakdown – FWB:0TB - TradingView
Theravance Biopharma Inc Revenue Breakdown – LS:A1137V - TradingView
Theravance Biopharma Inc (TBPH) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Liquidity Mapping Around (TBPH) Price Events - Stock Traders Daily
Precision Wealth Strategies LLC Takes $1.02 Million Position in Theravance Biopharma, Inc. $TBPH - MarketBeat
Theravance Biopharma Inc. (TBPH) Q1 2026 Earnings: Narrowing Losses as EPS Surprises to the UpsideEPS Revision Trend - dars.gov.et
Zymeworks Won’t Host Q2 Call Amid Proposed Theravance Deal - Stock Titan
Theravance Biopharma (TBPH) Hovers Near Support Amidst Quiet Trading SessionProtective Put - dars.gov.et
Are TBPH, IRDM, LCII, PATK Obtaining Fair Deals for their Shareholders? - Finansavisen
Theravance stock down 3% after Zymeworks announces buyout - MSN
Theravance Biopharma Inc Stock (TBPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):